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Abstract
Cancer research is drawing on the human genome project to develop new molecular-targeted treatments. This is an 
exciting but insufficient response to the growing, global burden of cancer, particularly as the projected increase in new 
cases in the coming decades is increasingly falling on developing countries. The world is not able to treat its way out of the 
cancer problem. However, the mechanistic insights from basic science can be harnessed to better understand cancer causes 
and prevention, thus underpinning a complementary public health approach to cancer control. This manuscript focuses 
on how new knowledge about the molecular and cellular basis of cancer, and the associated high-throughput laboratory 
technologies for studying those pathways, can be applied to population-based epidemiological studies, particularly in 
the context of large prospective cohorts with associated biobanks to provide an evidence base for cancer prevention. 
This integrated approach should allow a more rapid and informed translation of the research into educational and policy 
interventions aimed at risk reduction across a population.









The Tradition of Translational Cancer Research
Recent decades have yielded unprecedented advances in under-
standing the biological mechanisms underlying cancer devel-
opment and progression. Translation of this knowledge to the 
clinic promises new treatments tailored to exploit the molecular 
Achilles heel of a patient’s tumor (1–3). This has been described 
as personalized medicine, precision medicine, or, more con-
servatively, as stratified medicine and is popularized in the term 
“bench-to-bedside” research. In the cancer field, this is what is 
generally understood by translational cancer research. Thus, 
molecularly informed treatment points to marked improve-
ments in patient outcomes. However, cancer challenges are 
emerging that need additional and complementary solutions.
Because of population growth, increasing life expectancies 
and changes in underlying cancer incidence, the annual num-
ber of cases continues to rise globally, being expected to almost 
double in the next 20 years (4). Currently, close to half the people 
living within five years of a diagnosis (13.6 million) are from the 
richest countries, which comprise only one sixth of the world’s 
population (840 million) (5). Allied to this human burden is the 
spiraling cost of cancer therapy, which weighs ever more heavily 
on national budgets (6). However, the largest relative increases 
in new cases in the coming decades will occur in low-income 
countries (7), where even affordable and effective cancer treat-
ments remain largely unavailable and demands on inadequate 
cancer services will only continue to grow (8). Lower income 
countries therefore face a “double burden” as they transition to 
higher numbers of cancers on top of preexisting burdens from 
communicable diseases and malnutrition (7).
As a consequence, there is an urgent need for a global per-
spective on prevention strategies to complement the emerging 
benefits of new treatments in high-income countries and the 
improved access to existing treatments in low- and middle-
income countries. The shared nature of a number of risk factors 
for noncommunicable diseases means that benefits from pre-
vention will stretch beyond the confines of cancer (9).
Here, we do not attempt to address specific cancer preven-
tion and control priorities in low- and middle-income coun-
tries, which has been covered elsewhere (10,11). Rather, we 
focus on how the latest advances in understanding the mecha-
nisms of carcinogenesis offer a pathway to the identification of 
cancer risk factors and prevention strategies, which in turn may 
provide the improved evidence base for more effective cancer 
control in low- and middle-income countries. Specifically, we 
suggest an opportunity for translational cancer research to 
be “two-way”; the same foundation and novel technologies of 
basic science being used to develop new treatments should be 
applied to study the causes of cancer and its prevention, both 
through the avoidance of carcinogenic exposures and through 
the early detection (including screening) and treatment of 
disease. In providing reliable information on the relationship 
between exposures and risk, this integrated approach should 
therefore facilitate and underpin the translation of research 
findings into a range of different interventions (eg, educational, 
behavioral, policy-based) aimed at risk reduction across a given 
population.
The promise of primary prevention is based on recognition 
that most cancers have a lifestyle or environmental cause, and 
therefore in principal more than 50% could be prevented if the 
specific risk factors were identified and exposures controlled 
effectively (12–15). Primary prevention successes exist, with 
declining lung cancer rates following reductions in smoking, 
although these improvements are mainly limited to a few high-
income countries (16,17), plus the advent of vaccines against 
hepatitis B virus and human papillomavirus (HPV) to prevent 
liver and cervical cancers (18,19). However, primary prevention 
must be founded on identification of risk factors, and, although 
much progress has been made (20), for some common cancers 
(eg, prostate, kidney, pancreas, brain, hematological malignan-
cies) the identity of major risk factors remains largely obscure.
The long induction time of many precancerous lesions and 
cancers, stretching over many years if not decades, allows early 
detection through screening and consequent prognostic improve-
ments for cancers such as cervix, breast, and colorectal (21). 
However, this strategy of secondary prevention is frequently ham-
pered either by the inability to detect many types of cancer at early 
enough stages to permit successful treatment (eg, kidney, pan-
creas, ovary, brain, liver) or the inability to discriminate between 
screen-detected lesions that would or would not have progressed 
to malignancy (eg, for breast and prostate); under the latter cir-
cumstances, patients may be subject to overtreatment (22,23).
There is now a remarkable opportunity to address the appar-
ent impasse in both primary and secondary prevention by apply-
ing advances in the understanding of molecular carcinogenesis 
and the associated molecular tools to translational research. 
One must ask not whether but how the advances in basic sci-
ence leading to new avenues for cancer treatment might also 
provide a way forward in relation to cancer causation and pre-
vention globally (Figure 1).
Figure 1. Two-way translational cancer research.










The “omics” technologies used to probe the genome, epigenome, 
transcriptome, proteome, and metabolome offer opportunities to 
identify individual, groups, or patterns of biomarkers applicable 
to cancer prevention. Among the opportunities are: improved and 
novel approaches to exposure assessment, stratification of cancer 
cases by molecular subtype, elucidation of mechanistic pathways 
including “driver” mutations related to defined exposures, identi-
fication of molecular markers for early detection or prognosis, and 
use of biomarkers to evaluate the impact of interventions (24,25).
An outstanding challenge in studying etiology has been the 
inability to measure environmental and lifestyle exposures with 
the same precision or scope as for genetic analyses, leading to 
calls for a systematic determination of the human exposome to 
match the determination of the human genome (26,27). Indeed, 
while there have been large investments into novel technologies 
to define the underlying genetic causes of cancer (the human 
genome project and genome-wide association studies), there 
remains a substantial lag in investment to identify the major 
causes of cancer—namely environmental and lifestyle factors. 
Recently, new insights have been gained through application of 
the above-mentioned technologies. For example, Stransky et al. 
(28) performed whole-exome sequencing on head and neck 
tumors, revealing a different mutation rate and pattern in rela-
tion to HPV and smoking. Chronic low level benzene exposure 
was linked to different patterns of global gene expression (29) 
and several proof-of-principle studies used microarrays to inves-
tigate the impact of tobacco smoking on the transcriptome and 
epigenome (30,31). The comparison of metabolic profiles of colo-
rectal cancer patients and matched control patients by high-res-
olution mass spectrometry led to the indication of unexpected 
risk factors for the disease that have been linked to inflamma-
tion (32). Exciting advances are also being made in the ability to 
characterize individual dietary exposures. For example, an initial 
broad-based metabolomics approach resulted in the develop-
ment and validation of a new urinary biomarker for citrus fruit 
consumption (33). In this manner, innovations in measurement 
and data collection offer potential in unraveling the complex 
interactions between genetic and nongenetic factors.
The recognition that tumor classification requires integration 
of molecular characteristics for cancer treatment has its corollary 
in the field of etiology and prevention (34). Notably, the oppor-
tunity to subclassify tumors by their molecular profile means 
risk factors may be evaluated for specific molecular subgroups, 
offering the possibility to reveal associations cleared of the fog 
of heterogeneity (35,36). The potential of this strategy was dem-
onstrated in a case-cohort study of colorectal cancer, where the 
risk associated with acrylamide exposure was specific to patients 
with mutations characteristic of acrylamide in the K-ras and APC 
genes; the authors noted the need for caution in interpretation of 
these data, particularly given the number of subgroup analyses 
(37). Indeed, the molecular subclassification of tumors brings its 
own challenges of statistical power, implying that only the largest 
epidemiological studies will be suited to such an approach. This 
approach will also need to discriminate interpatient differences 
in driver and possibly passenger mutations relevant to etiology 
from the wider inter- and intratumor genetic and epigenetic het-
erogeneity (38–40). Further large-scale sequencing of the cancer 
genome and epigenome will refine the diversity and complexity 
of mutational and epigenetic processes underlying carcinogen-
esis, as well as molecular signatures associated with exposures.
An especially important development would be the iden-
tification of preneoplastic conditions at a point when medical 
treatments or lifestyle changes may cure or stop disease progres-
sion. The potential to reverse epigenetic alterations provides a 
basis for hope (25). Such an approach would be more analogous 
to the effective screening approaches in cardiovascular diseases 
(ie, detection and medical treatment of predisposing conditions 
such as hypertension, hypercholesterolemia), which are far 
less invasive and expensive than cancer screening approaches 
where surgical removal of lesions is mostly required.
Cancer chemoprevention has seen modest success to date 
with the use of supplementation, albeit reduced risks of colon 
and some other cancers have been reported with nonsteroidal 
anti-inflammatory agents (41). It may be of interest to revisit 
chemoprevention by tailoring the treatment either to the 
genetic profile of the individual or (pre-)neoplastic lesion (42). 
In addition, mechanism-based biomarkers also have promise as 
intermediate endpoints in intervention studies, providing justi-
fication for subsequent larger, longer-term studies with clinical 
endpoints (43).
In each of the above areas, the application of molecular sci-
ences and associated biomarkers permits a link from experi-
mental models through to epidemiology, notably in establishing 
biological mechanisms for exposure-disease associations at 
the population level. Experimental data provide indications 
that duration of exposure and dose are important in relation to 
gene expression changes and indicate how “omics” technolo-
gies could be “reverse engineered” to inform primary prevention 
(44). In time it is likely that this “common soil” of mechanistic 
research will contribute to a stronger basis for hazard identifica-
tion and risk assessment (45).
Tools lie idle without materials to work on. Research designs 
for treatment studies are feasible because of the relative ease of 
collecting information on patients in clinical settings. Excitingly, 
large prospective cohort platforms with well-characterized 
biospecimens provide the ideal context to study the long pre-
diagnostic period, and recent investments in these now enable 
studies relevant to etiology and prevention (46,47). Recognition 
that early life exposures are precursors to cancer later in life 
points to further development of cohort platforms and innova-
tive designs for studies over the life course (48,49).
Consortia have demonstrated a new commitment to global 
collaborations that deliver the large human studies needed to 
disentangle the biological complexity of cancer. The develop-
ment and sharing of new high-throughput methods, genomic 
databases, bioinformatics, and biostatistical tools therefore 
allows advances in laboratory sciences to be applied in epide-
miological studies with efficient processes to manage and inter-
rogate enormous databases. Investigators have an increasing 
ability to integrate molecular data across different platforms 
to obtain comprehensive portraits of cancer subtypes that may 
reveal etiology and prevention opportunities (eg, International 
Cancer Genome Consortium [icgc.org], Cancer Genome Atlas 
Network [cancergenome.nih.gov]). Recent large-scale mutation 
analysis by an international collaborative team identified diverse 
(more than 20)  mutation signatures among 30 cancer types 
(50). Extension of some of these approaches, particularly the 
establishment of prospective cohort studies, to low- and mid-
dle-income countries will provide valuable evidence for cancer 
prevention beyond the borders of the richer parts of the world.
Strategies to Heighten Impacts
To achieve the double benefits that could arise from transla-
tional cancer research involving both prevention and treatment, 
decisive action is needed at several levels.









First, the cancer research community must seize the oppor-
tunity to apply its tremendous skills and capacity to provide the 
evidence base for the next generation of cancer prevention that 
can lead to major impacts on a global scale. A balanced and inte-
grated approach that extends the reach and impact of the basic 
sciences would both complement and strengthen treatment-
oriented research. In this regard, there is a requirement for the 
optimal use of epidemiological resources as well as further tech-
nical and methodological development to ensure the laboratory 
methods are suited to population studies and related biobanks 
to gain maximum utility (51,52).
Second, there is a need to foster interdisciplinary research. 
This will require capacity building by training a new genera-
tion of researchers who work in teams involving both laboratory 
and population sciences and who have access to the necessary 
tools and infrastructure. There is a need for strategic recognition 
of the benefits of closer working relationships forged through 
shared planning, research, and resources across all the relevant 
disciplines. The building and supporting of such teams will yield 
benefits at the local level, as well as through consortia at the 
global level, as programs develop in low- and middle-income 
countries.
Third, clear communication by research leaders will allow 
all partners and stakeholders to embrace the need for stud-
ies of causes and prevention. With prevention not being done 
solely in the medical care system, the broader integration that 
is needed will allow new stakeholders to join (eg, experts in 
environment, food, water, health promotion, etc.). This can 
overcome one of the barriers to prevention research, which 
is that the private sector has favored the commercialization 
potential of only clinical interventions, whereas innovative 
products and services can be envisioned that are of global 
reach and interest. More active involvement of the general 
public and public agencies will also aid in communication as 
more effective ways are found to detect and report the benefits 
of prevention research.
Fourth, building on these strategies, advocacy is needed to 
convince politicians, policymakers, and funding agencies to pri-
oritize translational research into the causes and prevention of 
cancer on a scale not yet seen in comparison with bench-to-
beside research. Champions of prevention are needed to com-
plement the valuable and effective advocacy of cancer survivors. 
Molecular cancer epidemiology requires large and long-term 
investments in adaptation of new technologies for applica-
tion to large-scale population studies, as well as prioritization 
of infrastructure support to cohorts, biobanks, cancer regis-
tries, and other resources. Historically, there were few funders 
for such work, given the lack of obvious commercial benefits, 
but a strategic approach can lead to huge gains in health and a 
broad sharing of benefits. Public and charitable funding should 
be directed to translational prevention research to compensate 
for this relative lack of market value. The longer-term benefits 
of prevention in reducing the economic cost of cancer will pro-
vide a large return on this investment (53), in addition to the 
undoubted value in terms of reducing the social and emotional 
burden of the disease.
Conclusion
In summary, translational cancer research stands at an excit-
ing but critical point in time. It will not be possible to treat our 
way out of the cancer problem, either in aging Western societies 
or in poorer countries where health services are least able to 
serve the growing number of patients. What is needed now is a 
concerted effort to apply the remarkable advances in basic sci-
ence to contribute to cancer prevention, with an aspiration of 
reducing cancer burden and the associated global inequalities 
in health worldwide.
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